Table 1.
Baseline demographic characteristics of the patients
| Parameters | Levodopa (n=36) | Levodopa+pramipexole (n=27) | Levodopa+ropinirole (n=28) | Control (n=25) | P-value |
|---|---|---|---|---|---|
| Age | 67.0±11.8 | 60.7±8.3 | 64.4±9.9 | 61.9±9.5 | 0.063a |
| Gender | |||||
| Male | 23 (63.9%) | 17 (63.0%) | 15 (53.6%) | 14 (56%) | |
| Female | 13 (36.1%) | 10 (37.0%) | 13 (46.4%) | 11 (44%) | |
| Total | 36 | 27 | 28 | 25 | 0.812b |
| BMI (kg/m2) | 23.4±4.5 | 22.8±4.2 | 24.1±3.0 | 24±2.8 | 0.650a |
| Hypertension | 3 | 2 | 2 | 2 | 0.998b |
| Mean Hoehn and Yahr stage | 2.33±0.826 | 2.15±0.770 | 2.04±0.429 | 2.21±0.756 | 0.242a |
| Mean time period(months) | 59.1±54.7 (8-252) | 41.4±42.36 (6-132) | 43.9±36.5 (6-108) | - | |
| Mean daily levodopa dosage (mg) | 499.2±22.35 | 500.2±23.40 | 485±20.5 | - | 0.655a |
| Mean group drug dosage (mg) | 3.5±0.94x | 15.0±5.1y |
a
One-way analysis of variance,
b
Pearson chi-square,
x
pramipexole dosage,
y
ropinirole dosage.
BMI - body mass index